There are currently 83 active clinical trials seeking participants for Lymphoma research studies. The states with the highest number of trials for Lymphoma participants are Ohio, Illinois, California and New York.
A Study of TLN-254 in Participants with Relapsed or Refractory T-cell Lymphoma
NCT06733441
Recruiting
The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: Washington University School of Medicine, St. Louis, Missouri +1 locations
Conditions: Lymphoma
Register for Updates
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
NCT06218602
Recruiting
To find out if adding treatment with fecal microbiota transplantation (FMT) is effective at treating gut-related side effects of antibiotic treatment in participants who are receiving standard therapy with anti-CD19 chimeric antigen receptor T-cell (CAR-T cell) therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
NCT05940272
Recruiting
The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Memorial Sloan Kettering Cancer Center (All protocol activities), New York, New York +1 locations
Conditions: Lymphoma, B-Cell, Lymphoma, Large-cell Lymphoma, Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
Register for Updates
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
NCT02332668
Recruiting
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back after it had responded to previous treatment (responded means it stopped growing, gets smaller, or disappeared) * Refractory, which means cancer did not respond to previous treatment Pembrolizumab is... Read More
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
12/26/2024
Locations: Call for Information (Investigational Site 0019), Aurora, Colorado +13 locations
Conditions: Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
Register for Updates
IVIG for Infection Prevention After CAR-T-Cell Therapy
NCT05952804
Recruiting
This phase II trial compares the effects of immunoglobulin replacement therapy with a placebo for preventing infectious complications in patients receiving CD19 chimeric antigen receptor (CAR)-T cell therapy. Hypogammaglobulinemia is a common complication in patients who receive CD19 CAR-T cell therapy. This is a condition in which the level of immunoglobulins (antibodies) in the blood is low and the risk of infection is high. Immunoglobulin replacement therapy works by replacing the body's immu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/26/2024
Locations: City of Hope Cancer Center, Duarte, California +4 locations
Conditions: Lymphoma
Register for Updates
Pediatric PET/MR Image Registry
NCT03458520
Recruiting
The purpose of this study is to compare whole body magnetic resonance (MR) imaging, whole body positron emission tomography (PET)/MR imaging, and (if available) PET/Computed Tomography (CT) imaging for the diagnosis of tumors in children and young adults. Sensitivities, specificities and diagnostic accuracies of the different imaging modalities will be compared for significant differences.
Gender:
ALL
Ages:
40 years and below
Trial Updated:
12/17/2024
Locations: Stanford University, School of Medicine, Palo Alto, California
Conditions: Soft Tissue, Lymphoma, Osteosarcoma
Register for Updates
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
NCT05464719
Recruiting
To learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy. The safety and possible effects of the study therapy will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Large B-cell Lymphoma, Lymphoma
Register for Updates
Epcoritamab in Patients with Follicular Lymphoma Not Accomplishing a CR with Upfront Chemoimmunotherapy
NCT06510361
Recruiting
This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Lymphoma, Follicular Lymphoma, Lymphoma,Non-Hodgkin, Lymphoma, Non-Hodgkin's, Adult
Register for Updates
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
NCT06326463
Recruiting
The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come back after treatment (relapse). Primary Objective To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD70-CAR T cells in patients (≤21 years) with recurrent/refractory CD70+ hematological malignancies... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
12/16/2024
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Hematologic Malignancy, ALL, Childhood, AML, Childhood, Lymphoma, MDS
Register for Updates
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
NCT05683171
Recruiting
To find a recommended dose of valemetostat that can be given in combination with rituximab and lenalidomide to patients with follicular lymphoma. The safety and effects of this drug combination will also be studied
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Living Well With Lymphoma
NCT06047626
Recruiting
In this study the investigators are proposing to evaluate the efficacy, sustainability, and mechanisms of 3 months of individualized counseling of the FRD delivered by registered dietitians, over 8 sessions by phone/video conferencing on fatigue, quality of life, and associated symptoms in persistently fatigued lymphoma cancer survivors compared to 3 months of individualized counseling of the attention control (matched for time and frequency of interactions with the FRD) the General Health Curri... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Lymphoma
Register for Updates
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
NCT04940468
Recruiting
The primary objective of the study is to determine whether dietary intervention to increase fiber and decrease fat reduces C. difficile infection recurrence in a cohort of oncology patients.
Gender:
ALL
Ages:
9 years and above
Trial Updated:
12/03/2024
Locations: Childrens Hospital Colorado, Aurora, Colorado +1 locations
Conditions: Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Clostridium Difficile Infection
Register for Updates